Loading...
OTCM
NWPHF
Market cap210mUSD
Oct 09, Last price  
9.36
Name

Newron Pharmaceuticals SpA

Chart & performance

D1W1MN
OTCM:NWPHF chart
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
2.27%
Rev. 5Y
29.47%
Div Yld LY
—
Div Yld TTM
—
Revenues
19m
-62.78%
1,191,0004,024,0003,933,0002,542,000806,000280,0008,924,0003,539,0001,557,0002,380,0006,726,00013,428,0004,025,0007,038,0005,258,0005,762,0006,094,0009,057,00051,390,00019,126,000
Net income
-13m
L
-16,401,000-11,089,000-16,364,000-23,481,000-20,545,000-6,445,000-2,375,000-7,098,000-10,095,000-22,816,000-15,237,000-5,282,000-15,035,000-20,207,000-20,998,000-14,901,000-17,493,000-16,224,00015,843,000-13,239,000
CFO
33m
P
-9,630,000-13,866,000-19,932,000-23,056,000-19,127,000-4,942,0005,825,000-10,686,000-9,998,000-12,862,000-19,583,000-8,404,000-15,954,000-21,976,000-15,588,000-11,445,000-11,092,000-10,140,000-17,614,00032,560,322

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Founded in 1999 and headquartered in Bresso, Italy, Newron Pharmaceuticals S.p.A. is a clinical-stage biopharmaceutical enterprise focused on discovering and progressing therapeutic solutions. Its primary areas of research and development encompass conditions affecting the central and peripheral nervous systems, alongside pain management, with activities primarily conducted in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease and is also exploring its application for levodopa-induced dyskinesia. Furthermore, Newron is advancing Evenamide for various forms of schizophrenia, including those resistant to existing treatments, and Ralfinamide for the rare disease indication of neuropathic pain.

Key people

Chris Martin
Chairman of the Board · since 2025
Stefan Weber
Chief Executive Officer, Executive Director · since 2020
Roberto Galli
Chief Financial Officer · since 2023
Filippo Moriggia
Vice President - Operations · since 2022
Dennis Dionne
Vice President - Commercial Affairs · since 2017
Laura Faravelli
Vice President - Business Development · since 2023
Ravi Anand
Chief Medical Officer · since 2005
Luca Benatti
Non-Executive Independent Director · since 2014
Margarita Chavez
Non-Executive Independent Director · since 2024
Gillian Dines
Non-Executive Independent Director · since 2023
URL
https://www.newron.com/
IPO date
Dec 12, 2006
Employees
23
Domiciled in
IT
Incorporated in
IT
Headquarters & legal address
VIA MEUCCI, 3
BRESSO, MI 20091
IT

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT